Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvatinib and Pembrolizumab - ATLEP
Latest Information Update: 21 Oct 2022
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms ATLEP
Most Recent Events
- 13 Sep 2022 Primary endpoint has been met, (ORR obtained 12 weeks after start of treatment) , according to Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Final results presented at the 47th European Society for Medical Oncology Congress
- 21 Sep 2020 Results from a retrospective study and first results from the prospective phase II ATLEP trial assessing the implicating effectiveness of Lenvatinib and Pembrolizumab presented at the 45th European Society for Medical Oncology Congress